{
    "pmcid": "8447893",
    "qa_pairs": {
        "How do Class I nanobodies neutralize SARS-CoV-2 by targeting the spike protein?": [
            "Class I nanobodies bind to the RBD in the 'up' conformation, overlapping with the hACE2 binding site, thus blocking receptor attachment.",
            "Class I nanobodies bind to the RBD in the 'down' conformation, stabilizing it and preventing hACE2 access.",
            "Class I nanobodies bind to the NTD, causing conformational changes that prevent spike protein trimerization.",
            "Class I nanobodies recognize both 'up' and 'down' RBD conformations, targeting regions distinct from the hACE2 binding site."
        ],
        "What are nanobodies and what makes them suitable for therapeutic applications against SARS-CoV-2?": [
            "Nanobodies are single-domain antibodies derived from camelid antibodies, known for their small size and stability, allowing them to access cryptic epitopes and be used in inhalable formulations.",
            "Nanobodies are large, multi-domain antibodies derived from human antibodies, known for their ability to bind multiple epitopes simultaneously, making them suitable for intravenous administration.",
            "Nanobodies are synthetic peptides designed to mimic antibody binding, known for their rapid production and ability to be administered orally.",
            "Nanobodies are engineered proteins derived from bacterial sources, known for their high affinity to viral proteins and potential use in topical applications."
        ],
        "What are the advantages of producing nanobodies in microbial systems for therapeutic use against SARS-CoV-2?": [
            "Nanobodies can be produced in microbial systems, making them cost-effective and scalable, with stability and solubility allowing diverse routes of administration.",
            "Nanobodies can be produced in mammalian cell systems, ensuring high fidelity and post-translational modifications, with limited scalability.",
            "Nanobodies can be produced in plant-based systems, offering eco-friendly production with challenges in purification and consistency.",
            "Nanobodies can be produced in insect cell systems, providing rapid production with potential allergenic concerns."
        ],
        "What challenge does the high mutation rate of the SARS-CoV-2 spike protein pose for antibody efficacy, and how might nanobodies overcome this?": [
            "The high mutation rate poses challenges for antibody efficacy, but nanobodies targeting conserved regions may offer broader protection against emerging variants.",
            "The high mutation rate leads to rapid antibody degradation, but nanobodies with enhanced stability can resist these changes.",
            "The high mutation rate causes increased antibody cross-reactivity, but nanobodies with specific binding can reduce off-target effects.",
            "The high mutation rate results in decreased antibody solubility, but nanobodies with improved solubility can maintain therapeutic levels."
        ],
        "What structural technique is used to study how nanobodies bind to the SARS-CoV-2 spike protein?": [
            "Cryo-electron microscopy (cryo-EM) is used to study how nanobodies bind to the spike protein, revealing their modes of neutralization.",
            "X-ray crystallography is used to study how nanobodies bind to the spike protein, providing detailed atomic structures.",
            "Nuclear magnetic resonance (NMR) spectroscopy is used to study how nanobodies bind to the spike protein, offering insights into dynamic interactions.",
            "Mass spectrometry is used to study how nanobodies bind to the spike protein, identifying binding sites through peptide mapping."
        ]
    }
}